Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

305
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
305
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

320
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
320
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

293
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
293
Hypersensitivities01:30

Hypersensitivities

4.3K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
4.3K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

466
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
466
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

422
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
422

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sulforaphane reprograms the metabolomic landscape of chronic kidney disease: insights from NMR-based metabolomics.

Food & function·2026
Same author

Valorization of Co-Products from Barbecue Sauce Production Through Fermentation Processes.

Foods (Basel, Switzerland)·2026
Same author

Constrictive Pericarditis Due to Cryptococcus Neoformans in an Elderly Immunosuppressed Patient.

European journal of case reports in internal medicine·2026
Same author

Acute Spinal Cord Syndrome As the Initial Manifestation of Multiple Sclerosis: A Case Report.

Cureus·2026
Same author

Unraveling the Secret of Red Propolis for Health: Mechanism of Action and Future Perspectives.

The Journal of nutrition·2025
Same author

Spatiotemporal Variability of Dendroecological Indicators in Pedunculate Oak (Quercus robur L.) Tree-Rings Across Europe in Relation to Species Distribution Models.

Global change biology·2025

Related Experiment Video

Updated: Nov 17, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.5K

Mesalazine-induced Hypersensitivity Pneumonitis.

Francisca M Pereira1, Cristina Marques1, Teresa Boncoraglio1

  • 1Internal Medicine Department, Hospital Santa Maria Maior, Barcelos, Portugal.

European Journal of Case Reports in Internal Medicine
|February 15, 2021
PubMed
Summary

Mesalazine (5-ASA) can cause rare hypersensitivity pneumonitis in Crohn's disease patients. Discontinuing the drug and using corticosteroids improved symptoms in one case.

Keywords:
Mesalazinedrug reactionhypersensitivity pneumonitislung injuryulcerative colitis

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

614
Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

11.2K

Related Experiment Videos

Last Updated: Nov 17, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.5K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

614
Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

11.2K

Area of Science:

  • Pulmonology
  • Gastroenterology
  • Pharmacology

Background:

  • Inflammatory bowel disease (IBD) management often involves mesalamine (5-ASA).
  • Drug-induced lung injury is a potential adverse effect of various medications.
  • Distinguishing drug toxicity from IBD progression is clinically important.

Purpose of the Study:

  • To report a case of mesalazine-induced hypersensitivity pneumonitis.
  • To highlight the diagnostic challenges and management strategies for this rare condition.

Main Methods:

  • Case report of a 57-year-old woman with ulcerative proctitis.
  • Clinical presentation, diagnostic workup including bronchoalveolar lavage, and treatment response were analyzed.

Main Results:

  • The patient developed respiratory distress and cough, unresponsive to antibiotics.
  • Diagnosis of mesalazine-related hypersensitivity pneumonitis was established.
  • Symptoms resolved after mesalazine discontinuation and corticosteroid treatment.

Conclusions:

  • Mesalazine-related hypersensitivity pneumonitis is a rare but important diagnosis in patients with unexplained respiratory symptoms on 5-ASA.
  • Abrupt drug discontinuation is key for recovery; corticosteroids may be needed for severe cases.
  • Differentiating drug-induced pulmonary issues from IBD exacerbation is crucial for appropriate management.